Government Reduces Prices of 1,364 Cancer Medicines, Estimates ₹3,540 Crore Savings

The revised Maximum Retail Prices (MRPs) of 1,364 anti-cancer medicine formulations have come into effect, offering patients and their families potential relief from the high cost of cancer treatment. The government estimates that the price changes could help consumers save approximately ₹3,540.38 crore every year.

The decision is part of the government's efforts to make essential cancer medicines more affordable and improve access to treatment. Under the revised pricing framework, pharmacies and hospitals must follow the updated MRPs and cannot charge consumers more than the prices printed on the medicine packs.

NPPA Caps Trade Margins on 137 Anti-Cancer Drugs

The National Pharmaceutical Pricing Authority (NPPA), which operates under the Department of Pharmaceuticals in the Ministry of Chemicals and Fertilizers, has introduced the price-control measure by limiting trade margins on the MRPs of 137 identified anti-cancer drugs.

The decision follows recommendations made by an Expert Committee constituted by the Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare, on October 17, 2026. The revised prices became effective on November 9, 2026.

The initiative focuses on controlling excessive trade margins in the distribution and retail supply chain. It is intended to reduce the financial burden on cancer patients while maintaining the availability of essential medicines.

85 Pharmaceutical Companies Report Revised Prices

According to the Department of Pharmaceuticals, 85 pharmaceutical companies had reported revised MRPs for 1,364 anti-cancer formulations covering 121 drugs by November 8, 2026.

The price changes vary across brands and formulations. The government reported that 679 brands had recorded price reductions of more than 50 per cent. The highest reported reduction in MRP was 96.45 per cent.

Based on these revised prices, the estimated annual savings for consumers stand at ₹3,540.38 crore. The actual benefit for an individual patient will depend on the medicines prescribed, their brands and the treatment requirements.

No Chemist or Hospital Pharmacy Can Charge Above Revised MRP

The revised prices are applicable to retailers, chemists, hospital pharmacies and medical institutions supplying the affected medicines. They are not permitted to charge customers more than the revised MRP.

This is particularly important for patients who purchase cancer medicines directly from hospital pharmacies or through other medical institutions. Consumers should check the updated price before making a purchase and ensure that the amount charged does not exceed the MRP printed on the medicine pack.

The government has also directed stakeholders to follow the revised prices to ensure that patients receive the benefit of the pricing changes.

How Can Consumers Check Revised Anti-Cancer Medicine Prices?

Patients and their families can use official government resources to confirm the latest prices of affected medicines. The available options include:

• Revised MRP on medicine packs: Check the updated price printed on the medicine packaging.

• Pharma Sahi Daam mobile application: Use the app to search for medicine prices and verify the applicable MRP.

• NPPA website: Visit the official National Pharmaceutical Pricing Authority website at nppa.gov.in for updated price information and published lists.

Where Can Consumers Report Overcharging?

If a chemist, retailer or hospital pharmacy charges more than the revised MRP, consumers can raise a complaint through the government's designated channels.

The Department of Pharmaceuticals has advised consumers to use the Pharma Jan Samadhan portal to register complaints related to overcharging and other medicine-pricing concerns. They can also contact the NPPA helpline at 1800-111-255 for assistance.

Keeping the medicine packaging and purchase bill can help consumers provide relevant details when reporting a pricing complaint.

Making Cancer Treatment More Affordable in India

The revision of MRPs for anti-cancer formulations is an important step towards improving the affordability of cancer treatment in India. High medicine costs can create considerable financial pressure on patients and their families, particularly when treatment requires long-term medication.

By regulating trade margins and ensuring that revised prices reach consumers, the government aims to make selected cancer medicines more accessible. However, patients should continue to consult qualified healthcare professionals about their prescriptions and should not change or discontinue treatment based on price changes alone.

The effectiveness of this initiative will also depend on compliance by pharmaceutical companies, retailers and hospitals, along with consumers being aware of their rights and available complaint channels.